or in combination with didanosine should probably not be routinely recommended if other treatment options are available.
Although antiretroviral therapy using combinations of anti-HIV drugs has led to a dramatic decline of HIV-related morbidity and mortality, clinically important drug toxicities can limit the use of these agents (Arnaudo et al., 1991) . Peripheral neuropathy (PN) is one of the most frequent side effect that occurs during therapy with some nucleoside reverse transcriptase inhibitors (NRTIs), mainly zalcitabine (ddC), didanosine (ddI) and stavudine (d4T) (Brinkman et al., 1988; Cui et al., 1997) .
Several studies have shown that PN is more frequent when didanosine and stavudine are used in combination (Katlama et al., 2001; Lea & Faulds, 1996) . Thus, we designed a similar analysis to assess the relative risk of PN. We hypothesized that the use of NRTIs is associated with a higher risk of PN and aimed to determine the comparative incidence of PN associated with different NRTI regimens.
Data were obtained from patients continuously monitored for incident cases of PN at the HIV/AIDS Unit, University Teaching Hospital, Belgrade, Serbia and Montenegro. The study was approved by a local ethics committee and was conducted according to the Declaration of Helsinki.
During the baseline examination ( January 1996 to February 2002), all patients included in the study were treated with one or more NRTI in combination with protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (non-NRTIs). The medical records of all patients were reviewed for information on current and past health, medications, and known risk factors for PN.
None of the patients included in the study had a history or baseline signs of PN, characterized by pain (burning, aching, tingling). Patients with a high risk of PN due to alcoholism, deficiency of vitamin B12, pyridoxine or thiamine, as well as those on concomitant therapy with Peripheral neuropathy (PN) is a well-known adverse effect of treatment with nucleoside reverse transcriptase inhibitors (NRTIs). We performed a prospective follow-up study in HIVinfected patients on antiretroviral therapy containing NRTIs. The objective of this study was to examine the incidence of PN among patients using NRTI drugs. Data were obtained using medical records of patients continuously monitored for the efficacy and toxicity of antiretroviral therapy. The incident cases of PN were examined. Incidence rates of PN were calculated for each antiretroviral regimen that included zidovudine, zalcitabine, lamivudine, didanosine (ddI), stavudine (d4T) or didanosine+ stavudine. Poisson regression was used to compare the relative risk of PN for each regimen. A total of 112 HIV-infected patients were treated with at least one NRTI-containing regimen. Thirty-two cases of PN were recorded. The lowest incidence rate (IR) of 0.13 per 100 person-years occurred in patients treated with didanosine. The highest IR for PN occurred with the didanosine+stavudine combination (IR=0.18 per 100 person-years). Compared to didanosine alone, the relative risk of PN was 1.77 (95%CI, 0.52-2.12) for stavudine, and 1.76 (95%CI, 0.
95-2.49) for didanosine+stavudine. Other risk factors for PN included a low CD4 cell count and female sex. Our data show that the risk of PN is almost twice as high when stavudine is used alone or in combination with didanosine. The use of stavudine alone

Introduction
Materials and methods neurotoxic drugs (isoniazid, vincristine, dapsone) or with systemic medical conditions (diabetes mellitus) were excluded from the study. Patients receiving NRTIs were categorized into six groups. Each group was treated with at least one NRTIcontaining regimen: either zidovudine (250 mg BID), zalcitabine (0.75 mg TID) or lamivudine (150 mg BID, without dietary restrictions) alone, or didanosine (400 mg QD) and stavudine (40 mg BID) in combination or alone. Furthermore, a few patients (n=9) were treated with didanosine+stavudine+hydroxyurea and with didanosine+ hydroxyurea for a very short period (mean time 6 months). For statistical reasons, those patients were excluded from the final analysis.
PN screening and diagnosis on follow-up examinations included assessment of muscular strength, reflexes, threshold to vibration, pinprick and cold, and joint position sensations, performed according to a scheme standardized to exclude differences between investigators. All patients were systematically referred for a full neurological clinical examination and EMG (if needed) if they complained of any suspect symptoms and/or if they had any abnormal clinical signs. EMG records were taken with a Dantec Key point system (Medtronic Functional Diagnostics A/S, Skovlunde, Denmark) for motor and sensory nerve conduction velocity.
CD4 and plasma HIV RNA were measured at each visit. Plasma viral load was measured using the ultrasensitive polymerase chain reaction (PCR) method for HIV RNA detection (limits of quantification 50 copies/ml, respectively; Amplicor-Roche Diagnostic System, France).
Incidence rates for each of the NRTI-containing regimens were calculated according to a formula in which the number of cases of PN associated with a particular regimen represented the numerator and the total person-time accumulated on the corresponding regimen represented the denominator. If PN developed, only time to development was included. The crude relative risk (RR) of developing PN with 95% confidence intervals (CI) was calculated for each regimen. Poisson regression analysis was used to assess the risk of developing PN, adjusting for possible confounding effects from other variables. All NRTI-containing regimens were not kept in the model; only variates with a P<0.005 were retained in the final model.
Univariate and stepwise multivariate logistic regression models were used to asses the risk of developing PN for the following variables: CD4 cell count, age, gender, concomitant PI or non-NRTI drug use and duration of prior NRTI use.
Results
The total of 112 patients included in this study comprised 445.6 person-years of follow-up on NRTIs. Of these, 57 patients were male (50.9%) and 55 female (49.1%), with a mean age of 33.3 years (3-63). The median basal CD4 cell count was 205.7 cells/mm 3 and the median basal viral load was 4.6 log 10 copies/ml. Baseline characteristics of the study population are presented in Table 1 .
The NRTI-containing regimens included zidovudine (n=21), zalcitabine (n=18), lamivudine (n=22), didanosine (n=22), stavudine (n=45) and didanosine+stavudine (n=29). In total, 76 patients (67.9%) were on a single drug regimen, and 36 (32.1%) on a regimen containing ddI+d4T.
Out of the 112 patients, PN developed in 32, who complained of neurological symptoms with exhibited nerve conduction abnormalities, electric abnormalities, pain, and paresthesia with or without clinical abnormality.
The number of cases of PN, person-years and incidence rates (cases per 100 person-years) among the NRTI-containing regimens are presented in Table 2 . The lowest incidence rate (IR) for PN of 0.13 per 100 person-years was found in the didanosine group. The highest IR was in the didanosine+stavudine group (IR=0.18 per 100 person-years).
The adjusted RR of developing PN for each of the NRTI-containing regimens compared with didanosine alone are shown in Table 3 . For stavudine, the adjusted RR of PN was 1.77 (95% CI 0.52-2.12) compared with didanosine alone. The adjusted RR of PN for didano-sine+stavudine was 1.76 (95% CI 0.95-2.49).
The multivariate logistic analysis showed a CD4 cell count below 200×10 6 cells/mm 3 and female sex to be associated with developing PN. In contrast, age and concomitant PI or non-NRTI drug use, as well as duration of prior NRTI use, were not associated with PN after adjusting for these factors (multivariate logistic regression, data not shown). 
Discussion
Our analysis indicates that the risk of PN is almost twice as high when stavudine is used alone compared with didanosine alone. ddI seems to inhibit the DNA polymerase-γ that is necessary for maintaining the normal status of mitochondrial DNA, whereas d4T does not (Brinkman, 1988; Lelacheur, 1991) . However, d4T has been recognized as a potential cause of PN (Moore, 2000; Moreas 1991; Moyle, 1998) . Our study provides evidence that PN is closely related to d4T therapy. ddI+d4T combination was associated with an almost two-fold increase in the relative risk of PN, as assessed by Poisson regression. These data are similar to other reports (Katlama et al., 2001; Reliquet et al., 2001) . The usage of other NRTIs such as zidovudine, zalcitabine and lamivudine did not appear to increase the risk of developing PN. Furthermore, the risk of PN was neither increased with concomitant use of PI or non-NRTI drugs. The specific mechanism of NRTI-induced PN is not yet known. The recognized adverse effects of NRTIs include myopathy, PN, acute pancreatitis, anaemia, neutropenia, hepatic toxicity and lactic acidaemia. Most of these complications are thought to be due to toxic effects on the mitochondria (Schindzierlorz et al., 1994) . NRTIs are phosphorylated intracellularly into dideoxynucleoside triphosophates. These compounds compete with the natural substrates for HIV reverse transcriptase (deoxythymidine triphosophates), but since they lack a 3′ hydroxyl group, the effect is termination rather than growth of the DNA chain. They inhibit DNA polymerase-γ, the enzyme required for replication of mitochondrial (mt-)DNA, thus lowering the mt-DNA levels. (Simpson & Olney, 1992) . The significance of the low mt-DNA concentrations is emphasized by the occurrence of similar problems in patients with DNA depletion due to genetic defects (Sommadossi, 1995) .
Previous studies showed marked immunosuppression and advanced stage of HIV infection to be the major factors predicting the occurrence of PN (Arnaudo et al., 1991; Moyle & Sadler, 1998; Somadossi, 1995) . Potential confounding factors assessed in our analysis were CD4 count below 200×10 6 cells/mm 3 and gender (female sex). Marked immunosuppression and advanced stage of HIV infection (CD4 count below 200×10 6 cells/mm 3 ) may predict the occurrence of PN (Reliquet et al., 2001) . Increased sensitivity of women to the toxicity of NRTI-containing regimens may be due to a smaller body mass index (Sommadossi, 1993) .
In summary, we found that both d4T alone and concomitant usage of ddI and d4T resulted in a doubling in the RR for developing PN in our patient series. These results suggest that the use of d4T alone or in combination with ddI probably should be discouraged because of the increased risk of toxicity.
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